Abnormalities of Toll-like receptors (TLRs) have been implicated in the pathophysiology of depression and suicide. Interactions of TLRs with pathogen-associated molecular patterns (PAMP) and damage-associated molecular patterns (DAMP) initiate signaling through myeloid differentiation primary response-88 (MyD88) and produce cytokines through the activation of the transcription factor nuclear factor kappa beta (NF-kB). We have earlier shown an increase in the protein and mRNA expression of TLR3 and TLR4 in the prefrontal cortex (PFC) of depressed suicide (DS) subjects compared with normal control (NC) subjects. To examine if other TLRs are altered in postmortem brain, we have now determined the protein and mRNA expression of other TLRs (TLR1, TLR2, TLR5, TLR6, TLR7, TLR8, TLR9 and TLR10) in the PFC of DS, depressed non-suicide (DNS), non-depressed suicide (NDS) and NC subjects. We determined the protein expression by Western blot and mRNA expression levels by real-time PCR (qPCR) in the PFC of 24 NC, 24 DS, 12 DNS and 11 NDS subjects. Combined with our previous study of TLR3 and TLR4, we found that the protein expression of TLR2, TLR3, TLR4, TLR6 and TLR10, and mRNA expression of TLR2 and TLR3 was significantly increased in the DS group compared with NC group. This study demonstrated that certain specific TLRs are altered in DS subjects, and hence those TLRs may be appropriate targets for the development of therapeutic agents for the treatment of suicidal behavior.
Introduction
Abnormalities of the immune function have been implicated in the pathophysiology of depression and suicide (Drexhage et al., 2011; Steiner et al., 2008) . Cytokines, which are a heterogeneous group of messenger molecules produced by immunocompetent cells, play an important role in mediating immune functions. Evidence that cytokines might play an important role in inducing depression is derived from both animal and human studies, as described below
The administration of cytokines to animals and humans induces symptoms that have been termed as sickness behavior (Dantzer, 2001) . This sickness behavior is characterized by symptoms such as weakness, malaise, restlessness, inability to concentrate, lethargy, decreased interest in surroundings and reduced food intake, all of which are depression-like symptoms (Dantzer, 2001) .
About 30-40% of patients receiving chronic exogenous administration of IL-2 for renal cell cancer and metastatic melanoma experienced fatigue, anorexic sleep disorders, depressed mood, anxiety and cognitive dysfunction (Dantzer and Kelley, 2007) . These symptoms are also seen in patients receiving chronic cytokine administration for hepatitis (Capuron et al., 2002) . The depressive symptoms may be alleviated by the administration of antidepressants, such as paroxetine (Capuron et al., 2002) . These symptoms appear to be prevented by prophylactic therapy (Dantzer, 2006) . It has been shown that paroxetine has an effect on depressive symptoms but not on the fever, fatigue, and anorexia associated with sickness behavior (Dantzer, 2006) .
In humans, the involvement of cytokines in the regulation of behavioral symptoms has been studied by the application of bacterial endotoxin LPS in human volunteers (Reichenberg et al., 2001 ). LPS, a potent activator of proinflammatory cytokines was found to induce fever, anorexia, anxiety, depressed mood and cognitive impairment, and the levels of anxiety, depressed mood, depression and cognitive impairment were found to be related to the levels of circulating cytokines (Miller et al., 2009; Reichenberg et al., 2001 Reichenberg et al., , 2002a .
The other major line of evidence that cytokines may play a role in depression is derived from the observation that the levels of proinflammatory cytokines in the serum and cerebrospinal fluid (CSF) is increased in patients with depression (see review by Dowlati et al. (2010) , Hiles et al. (2012) and suicidal behavior (Black and Miller, 2015) Depression and stress are major risk factors for suicidal behavior, and it has also been shown that stressful events cause changes in https://doi.org/10.1016/j.bbi.2018.09.024 Received 24 August 2017; Received in revised form 11 September 2018; Accepted 24 September 2018
